205 related articles for article (PubMed ID: 12796362)
41. Identical genetic changes in different histologic components of Wilms' tumors.
Zhuang Z; Merino MJ; Vortmeyer AO; Bryant B; Lash AE; Wang C; Deavers MT; Shelton WF; Kapur S; Chandra RS
J Natl Cancer Inst; 1997 Aug; 89(15):1148-52. PubMed ID: 9262253
[TBL] [Abstract][Full Text] [Related]
42. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers.
Takahashi M; Yang XJ; Sugimura J; Backdahl J; Tretiakova M; Qian CN; Gray SG; Knapp R; Anema J; Kahnoski R; Nicol D; Vogelzang NJ; Furge KA; Kanayama H; Kagawa S; Teh BT
Oncogene; 2003 Oct; 22(43):6810-8. PubMed ID: 14555994
[TBL] [Abstract][Full Text] [Related]
43. Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic features.
Mrowka C; Schedl A
J Am Soc Nephrol; 2000 Nov; 11 Suppl 16():S106-15. PubMed ID: 11065340
[TBL] [Abstract][Full Text] [Related]
44. Wilms' tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: a possible mechanism in sporadic Wilms' tumor.
Rong Y; Cheng L; Ning H; Zou J; Zhang Y; Xu F; Liu L; Chang Z; Fu XY
Cancer Res; 2006 Aug; 66(16):8049-57. PubMed ID: 16912181
[TBL] [Abstract][Full Text] [Related]
45. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
46. Clear cell sarcoma of the kidney expresses insulinlike growth factor-II but not WT1 transcripts.
Yun K
Am J Pathol; 1993 Jan; 142(1):39-47. PubMed ID: 8424465
[TBL] [Abstract][Full Text] [Related]
47. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.
Patek CE; Fleming S; Miles CG; Bellamy CO; Ladomery M; Spraggon L; Mullins J; Hastie ND; Hooper ML
Hum Mol Genet; 2003 Sep; 12(18):2379-94. PubMed ID: 12915483
[TBL] [Abstract][Full Text] [Related]
48. The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1.
Wagner N; Wagner KD; Xing Y; Scholz H; Schedl A
J Am Soc Nephrol; 2004 Dec; 15(12):3044-51. PubMed ID: 15579507
[TBL] [Abstract][Full Text] [Related]
49. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia.
Barragán E; Cervera J; Bolufer P; Ballester S; Martín G; Fernández P; Collado R; Sayas MJ; Sanz MA
Haematologica; 2004 Aug; 89(8):926-33. PubMed ID: 15339675
[TBL] [Abstract][Full Text] [Related]
50. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
51. Novel frame shift mutations ('A' deletion) observed in exon 9 of Wilms' tumor (WT1) gene in a patient reported with glomerulosclerosis.
Pasupuleti SK; Katari V; Lokanathan S; Uppu VP; Thummaginjala SS; Akkamgari RP; Ayapati T; Kottu R; Potukuchi VG
Gene; 2014 Aug; 546(1):63-7. PubMed ID: 24853201
[TBL] [Abstract][Full Text] [Related]
52. Significant reduction of WT1 gene expression, possibly due to epigenetic alteration in Wilms' tumor.
Satoh Y; Nakagawachi T; Nakadate H; Kaneko Y; Masaki Z; Mukai T; Soejima H
J Biochem; 2003 Mar; 133(3):303-8. PubMed ID: 12761165
[TBL] [Abstract][Full Text] [Related]
53. Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation.
Huang L; Mokkapati S; Hu Q; Ruteshouser EC; Hicks MJ; Huff V
Neoplasia; 2016 Feb; 18(2):71-81. PubMed ID: 26936393
[TBL] [Abstract][Full Text] [Related]
54. [Molecular genetics of Wilms' tumor].
Papezová M; Mares J; Goetz P
Cas Lek Cesk; 2001 Jun; 140(11):323-7. PubMed ID: 11431850
[TBL] [Abstract][Full Text] [Related]
55. WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts.
Hosono S; Luo X; Hyink DP; Schnapp LM; Wilson PD; Burrow CR; Reddy JC; Atweh GF; Licht JD
Oncogene; 1999 Jan; 18(2):417-27. PubMed ID: 9927198
[TBL] [Abstract][Full Text] [Related]
56. Mutations/deletions of the WT1 gene, loss of heterozygosity on chromosome arms 11p and 11q, chromosome ploidy and histology in Wilms' tumors in Japan.
Nakadate H; Yokomori K; Watanabe N; Tsuchiya T; Namiki T; Kobayshi H; Suita S; Tsunematsu Y; Horikoshi Y; Hatae Y; Endo M; Komada Y; Eguchi H; Toyoda Y; Kikuta A; Kobayashi R; Kaneko Y
Int J Cancer; 2001 Nov; 94(3):396-400. PubMed ID: 11745420
[TBL] [Abstract][Full Text] [Related]
57. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations.
Bardeesy N; Beckwith JB; Pelletier J
Cancer Res; 1995 Jan; 55(2):215-9. PubMed ID: 7812946
[TBL] [Abstract][Full Text] [Related]
58. Genetics of Wilms' tumor.
Coppes MJ; Egeler RM
Semin Urol Oncol; 1999 Feb; 17(1):2-10. PubMed ID: 10073400
[TBL] [Abstract][Full Text] [Related]
59. Immunotherapeutic targeting of Wilms' tumor protein.
Hutchings Y; Osada T; Woo CY; Clay TM; Lyerly HK; Morse MA
Curr Opin Mol Ther; 2007 Feb; 9(1):62-9. PubMed ID: 17330403
[TBL] [Abstract][Full Text] [Related]
60. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities.
Haruta M; Arai Y; Sugawara W; Watanabe N; Honda S; Ohshima J; Soejima H; Nakadate H; Okita H; Hata J; Fukuzawa M; Kaneko Y
Genes Chromosomes Cancer; 2008 Aug; 47(8):712-27. PubMed ID: 18464243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
